A policy issued by the Department of Health and Human Services (HHS), spearheaded by Robert F. Kennedy Jr., aims to ease access to unproven peptide drugs. This policy directs the Food and Drug Administration (FDA) not to take action against specialty pharmacies selling a handful of peptides, including BPC-157, TB-500, and KPV.
FDA and HHS Involvement
These chemicals are currently considered illegal drugs by the FDA because they have not undergone the agency’s rigorous review process for safety and effectiveness. The policy reflects Kennedy’s determination that it advances patient choice and protects Americans from online peptide sales. FDA scientific staffers opposed the changes, citing concerns about undermining the agency’s mission to limit unproven health products. HHS officials initially sought a regulation allowing these peptides to be used by compounding pharmacies, but this approach was abandoned.